Tenpoint Therapeutics, Ltd. to Participate in Upcoming Investor Conference

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced participation in an upcoming investor conference. The Company’s lead investigational asset, BRIMOCHOL™ PF, is designed to be the first and only combination therapy for presbyopia and has received a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. Tenpoint Therapeutics is actively advancing preparations for a commercial launch in 1H 2026.

• RBC Capital Markets Healthcare Private Company Virtual Conference, December 11. Henric Bjarke, CEO, will present in a fireside discussion at 10:40 a.m. ET on December 11, and management will host 1x1 meetings.

To request a meeting with the Tenpoint Therapeutics team, please contact the RBC conference representatives or email the Company’s investor relations team at [e-mail].

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the NDA and has received a PDUFA date from the US FDA of Jan 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy.

To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.